EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Trastuzumab Deruxtecan–Induced Interstitial Lung Disease: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Evidence

Ali Kaan Güren iD, Nazım Can Demircan iD, Murat Sarı, Osman Köstek, İbrahim Vedat Bayoğlu

Cancer Control · 2026-05 · 33

DOI: 10.1177/10732748261451083 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Cancer Control, online erschienen am 09.05.2026. Verfasst von Ali Kaan Güren und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Trastuzumab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease/pneumonitis (ILD) represents a clinically significant and potentially fatal toxicity. Discrepancies exist regarding its reported frequency and severity between clinical trials (CTs) and real-world data (RWD). This meta-analysis aims to evaluate the incidence of T-DXd-related ILD and investigate its differences between CTs and RWD.

Methods

A systematic review and meta-analysis was conducted in accordance with the PRISMA guidelines. Databases were searched from their inception through January 2026. CTs and real-world studies reporting T-DXd-related ILD were included in the analysis. Pooled incidences for all-grade, grade ≥3, and fatal ILD were calculated using random-effects models. Subgroup analyses comparing CTs and RWD, and meta-regression analyses for relevant outcomes were performed.

Results

Thirty-five studies (19 CTs, 16 RWD) including 6840 patients were analyzed. The pooled incidence was 8.8% for all-grade ILD, 1.6% for grade ≥3 ILD, and 0.26% for fatal ILD. RWD was independently associated with lower reported rates of all-grade and fatal ILD, while prior lines of therapy were the main predictor of grade ≥3 ILD.

Conclusion

ILD risk with T-DXd differs by severity and data source. Vigilant monitoring is essential, particularly in heavily pretreated patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung Diseases, InterstitialTrastuzumabHumansClinical Trials as Topic

Stichwörter der Autor:innen

clinical trialsinterstitial lung diseasemeta-analysisreal-world datatrastuzumab deruxtecan

Substanzen

Trastuzumab

Autor:innen und Institutionen

  • Department of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey.

ORCID-Profile: Ali Kaan Güren, Nazım Can Demircan

Zitieren

APA

Güren, A. K., Demircan, N. C., Sarı, M., Köstek, O., & Bayoğlu, İ. V. (2026). Trastuzumab Deruxtecan–Induced Interstitial Lung Disease: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Evidence. Cancer Control, 33. https://doi.org/10.1177/10732748261451083

Vancouver

Güren AK, Demircan NC, Sarı M, Köstek O, Bayoğlu İV. Trastuzumab Deruxtecan–Induced Interstitial Lung Disease: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Evidence. Cancer Control. 2026;33. doi:10.1177/10732748261451083

BibTeX
@article{Gren2026,
  author = {Güren, Ali Kaan and Demircan, Nazım Can and Sarı, Murat and Köstek, Osman and Bayoğlu, İbrahim Vedat},
  title = {Trastuzumab Deruxtecan–Induced Interstitial Lung Disease: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Evidence},
  journal = {Cancer Control},
  year = {2026},
  volume = {33},
  doi = {10.1177/10732748261451083}
}
Kostenlos starten →